Abbreviated Course Rituximab for Auto-immune Disease Refractory to Standard Immunosuppressive Therapy
Phase 2
- Conditions
- Auto-immune disordersInflammatory and Immune System - Autoimmune diseases
- Registration Number
- ACTRN12606000495527
- Lead Sponsor
- Melbourne Health - The Royal Melbourne Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Auto-immune disease refractory to or intolerant of conventional immunosuppressive therapy, Informed consent.
Exclusion Criteria
Hepatitis B or C positivity.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method